JP2005533787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533787A5 JP2005533787A5 JP2004512774A JP2004512774A JP2005533787A5 JP 2005533787 A5 JP2005533787 A5 JP 2005533787A5 JP 2004512774 A JP2004512774 A JP 2004512774A JP 2004512774 A JP2004512774 A JP 2004512774A JP 2005533787 A5 JP2005533787 A5 JP 2005533787A5
- Authority
- JP
- Japan
- Prior art keywords
- manufacture
- drugs
- treatment
- xenon
- antispasmodic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 18
- 229940079593 drugs Drugs 0.000 claims 17
- 238000004519 manufacturing process Methods 0.000 claims 17
- 229910052724 xenon Inorganic materials 0.000 claims 13
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon(0) Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims 13
- 239000000812 cholinergic antagonist Substances 0.000 claims 8
- 230000017531 blood circulation Effects 0.000 claims 6
- 239000007789 gas Substances 0.000 claims 6
- 210000004556 Brain Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 206010057668 Cognitive disease Diseases 0.000 claims 3
- 206010047163 Vasospasm Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 2
- 230000002921 anti-spasmodic Effects 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 238000006213 oxygenation reaction Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 210000001736 Capillaries Anatomy 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 230000002490 cerebral Effects 0.000 claims 1
- 230000003727 cerebral blood flow Effects 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000002980 postoperative Effects 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 230000000304 vasodilatating Effects 0.000 claims 1
Claims (9)
- キセノン又はキセノン含有ガス混合物を含有する鎮痙剤。
- キセノンが薬理学的に有効な量で含まれている、請求項１記載の鎮痙剤。
- 鎮痙剤がＮＯ又はＮＯ源を治療学的に有効な量で含有する、請求項１又は２記載の鎮痙剤。
- キセノン又はキセノン含有ガス及び、経口又は静脈内に投与される鎮痙剤を含有する、痙攣の治療に際して同時に、別々に又は時間的に区別して使用するための組み合わせ製剤としての鎮痙剤。
- 鎮痙剤を血管痙攣の治療のために使用する、請求項４記載の鎮痙剤。
- キセノン及びＮＯ源を含有するか、又はキセノン含有ガス及びＮＯ源を含有する薬剤。
- 痙攣の治療用の薬剤の製造のため、血管痙攣の治療用の薬剤の製造のため、脳血管痙攣の治療用の薬剤の製造のため、血行障害の治療用の薬剤の製造のため、特に脳内の血行障害の治療用のガス状の薬剤の製造のため、脳血流欠損の治療用の薬剤の製造のため、冠状動脈血流欠損の治療用の薬剤の製造のため、認知障害の治療のための薬剤の製造のため、卒中発作の治療用の薬剤の製造のため、卒中発作の予防用の薬剤の製造のため、脳内の酸素供給の改善用の薬剤の製造のため、虚血後症候群の治療用の薬剤の製造のため又は脳内の血行促進用の薬剤の製造のため、生体の酸素化の改善用の薬剤の製造のため、脳内の酸素化の改善用の薬剤の製造のための、キセノン又はキセノン含有ガス混合物及び場合によりＮＯ源の使用。
- 人体の毛細血流域又は前毛細血流域での血管拡張作用を有する薬剤の製造のための、キセノン又はキセノン含有ガス混合物の使用。
- 認知機能障害、また術後の認知機能障害の予防用及び／又は治療用の薬剤の製造のための、キセノン又はキセノン含有ガス混合物及び場合によりＮＯ源の使用。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10226191 | 2002-06-12 | ||
| DE10226193 | 2002-06-12 | ||
| DE10227974 | 2002-06-22 | ||
| PCT/EP2003/006190 WO2003105872A1 (de) | 2002-06-12 | 2003-06-12 | Xenonhaltiges spasmolytikum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533787A JP2005533787A (ja) | 2005-11-10 |
| JP2005533787A5 true JP2005533787A5 (ja) | 2006-08-03 |
Family
ID=29715725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004512774A Pending JP2005533787A (ja) | 2002-06-12 | 2003-06-12 | キセノン含有の鎮痙剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050244508A1 (ja) |
| EP (1) | EP1515731A1 (ja) |
| JP (1) | JP2005533787A (ja) |
| CN (1) | CN1668316A (ja) |
| AU (1) | AU2003245934A1 (ja) |
| DE (1) | DE10327000A1 (ja) |
| WO (1) | WO2003105872A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008132239A1 (en) * | 2007-04-30 | 2008-11-06 | Nnoxe Pharmaceutiques Inc | Pharmaceutical composition comprising at least one thrombolytic agent (a) and at least one gas (b) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon |
| FR2996459B1 (fr) * | 2012-10-09 | 2015-02-06 | Air Liquide | Utilisation d'un melange argon/xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique |
| FR2996458B1 (fr) * | 2012-10-09 | 2015-02-27 | Air Liquide | Utilisation de xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique |
| AU2014233018A1 (en) | 2013-03-15 | 2015-10-01 | The Board Of Regents Of The University Of Texas System | Liquids rich in noble gas and methods of their preparation and use |
| US20210338713A1 (en) * | 2020-05-04 | 2021-11-04 | Brain Cancer Research Institute | Reduction of Pulmonary Inflammation Using Therapeutic Gas Mixtures |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1601366A (en) * | 1977-06-21 | 1981-10-28 | Nat Res Dev | Lasers |
| US5228434A (en) * | 1991-07-16 | 1993-07-20 | Praxair Technology, Inc. | Mixture for anesthesia |
| WO1997015311A1 (fr) * | 1995-10-20 | 1997-05-01 | L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | Composition a base de monoxyde d'azote en tant que medicament |
| DE19709704C2 (de) * | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| CA2306096A1 (en) * | 1997-10-15 | 1999-04-22 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| US6656452B1 (en) * | 1997-10-21 | 2003-12-02 | The General Hospital Corporation | Use of inhaled NO as anti-inflammatory agent |
| DE19938800A1 (de) * | 1999-08-16 | 2001-02-22 | Stefan Huebner | Medizinisches Präperat zur Verabreichung flüchtiger Stoffe |
| FR2812197B1 (fr) * | 2000-07-27 | 2003-01-03 | Air Liquide Sante Int | Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches |
| FR2812545B1 (fr) * | 2000-08-03 | 2003-03-28 | Air Liquide Sante Int | Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur |
| DE10045845A1 (de) * | 2000-09-14 | 2002-04-04 | Messer Griesheim Gmbh | Xenon als Arzneimittel |
| US6596206B2 (en) * | 2001-03-30 | 2003-07-22 | Picoliter Inc. | Generation of pharmaceutical agent particles using focused acoustic energy |
-
2003
- 2003-06-12 DE DE2003127000 patent/DE10327000A1/de not_active Withdrawn
- 2003-06-12 CN CNA038165775A patent/CN1668316A/zh active Pending
- 2003-06-12 WO PCT/EP2003/006190 patent/WO2003105872A1/de active Application Filing
- 2003-06-12 EP EP03738021A patent/EP1515731A1/de not_active Withdrawn
- 2003-06-12 US US10/517,722 patent/US20050244508A1/en not_active Abandoned
- 2003-06-12 AU AU2003245934A patent/AU2003245934A1/en not_active Abandoned
- 2003-06-12 JP JP2004512774A patent/JP2005533787A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10526303B2 (en) | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto | |
| ES2431570T3 (es) | Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención | |
| ES2644942T3 (es) | Métodos y composiciones para el tratamiento del trastorno por déficit de atención | |
| ES2653852T3 (es) | Composiciones farmacéuticas que contienen ligandos del receptor de dopamina y procedimientos de tratamiento usando ligandos del receptor de dopamina | |
| JP2003503450A5 (ja) | ||
| JP2006523216A5 (ja) | ||
| ES2399348T3 (es) | Composición farmacéutica que comprende un agente antiparasitario y una sustancia activa elegida entre timol, eugenol y carvacrol | |
| WO2005063297A3 (en) | Melatonin combination therapy for improving sleep quality | |
| AR037491A1 (es) | Bromuro de (1alfa,2beta,4beta,5alfa,7beta,)-7-[(hidroxi-di-2tienil-acetil)oxi]-9,9-dimetil-3-oxa-9-azoniatriciclo.[3.3.1.0 /2,4]-nonano cristalino en la forma anhidra (bromuro de tiotropio cristalino anhidro) , un procedimiento para su preparacion , su utilizacion para la preparacion de un medicamen | |
| WO2005077950A3 (en) | Medicaments with hm74a receptor activity | |
| EA200801967A1 (ru) | Дозированная лекарственная форма на основе циклогексанового полиола (варианты), способ ее получения, способ лечения болезни альцгеймера с ее помощью и циклогексановый полиол в качестве средства при изготовлении лекарственного средства | |
| HUP0401201A2 (hu) | Flibanserin stabil polimorfja, ipari eljárás előállítására és alkalmazása gyógyszerek előállítására | |
| ATE531361T1 (de) | Neue pharmazeutische dosierform und herstellungsverfahren | |
| JP2007513993A5 (ja) | ||
| JP2007516193A5 (ja) | ||
| WO2005016867A3 (en) | Anthranilic acid derivatives and their use as activators of the hm74a receptor | |
| JP2007517049A (ja) | 再発性病状を治療するための組成物および方法 | |
| JP2005533787A5 (ja) | ||
| ES2238781T3 (es) | Utilizacion de la mirtazapina para la obtencion de un medicamento para el tratamiento de las apneas del sueño. | |
| JP2016504405A (ja) | ガレヌス製剤の有効成分の投与剤形 | |
| Sharma | Practitioners' Section-Novel phosphodiesterase-5 inhibitors: Current indications and future directions | |
| JP2005508963A5 (ja) | ||
| JP2006504735A5 (ja) | 絨毛性性腺刺激ホルモンを含む慢性骨盤疼痛症候群の治療用組成物 | |
| RU2003127718A (ru) | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости | |
| ES2661835T3 (es) | Enantiómero (R) de la lauflumida a más del 95%ee |